Fueling bold approaches
Flu Lab's mission is to eliminate the threat of influenza, a highly contagious virus that causes annual epidemics of disease and poses an ever-present risk of a catastrophic pandemic. To achieve this, Flu Lab finds and supports efforts that approach persistent problems in new and dynamic ways, with actionable results.
Through grantmaking, investing, and partner collaborations, Flu Lab seeks to help grantees and early-stage companies develop innovations that will help accelerate the availability of new solutions for global influenza challenges.
Awarded Grants and Investments
We are pleased to showcase current and past grantees and investments. For news and updates about our grants and investments, visit News + More.
University of Oxford
Developing a broadly protective influenza vaccine with transmission blocking efficacy.
£2,300,738 / June 2024
Icahn School of Medicine
Leading virus species identification and analysis for the New York City Virus Hunters community science program.
$1,073,042 / May 2024
St. Jude Children's Research Hospital
Incorporating genotype accessibility into influenza virus evolutionary predictions.
$1,370,388 / May 2024
Center for Green Schools
Equips schools and education stakeholders with information and guidance to improve ventilation and air filtration in classrooms.
$955,710 / May 2024, October 2021, August 2021
Scout
To advance the development of Respiratory Scout, a low-cost molecular test to diagnose influenza and other respiratory virus infections.
$161,000 / March 2024
University of Michigan
Establishing FluGuardians, a new birth cohort study to gain a deeper understanding of the development of influenza immunity.
$6,663,637 / March 2024
Center for Radiological Research
Conducting far-UVC light ocular and stratum corneum safety studies in diverse human populations.
$1,662,490 / March 2024
Vivaldi Biosciences
Evaluating the immunogenicity and protection of an intranasal universal influenza vaccine candidate against wild-type transmission in ferrets.
$406,000 / December 2023
Washington University in St. Louis
Creating a handheld, rapid result, breath-based diagnostic for the detection of multiple respiratory pathogens.
$3,595,280 / November 2023
Panoplia Labs
Developing inhalable, broad-spectrum antivirals that provide extended prophylaxis against infectious diseases.
$159,000 / October 2023
PicturaBio
Creating the first universal testing platform to provide fast, accurate, digital imaging-based identification for infectious disease pathogens.
Seed / October 2023
Fishell Institute for Biomedical Devices
Adapting graphene-based biosensors for the selective detection of influenza.
$1,348,454 / June 2023
Emory University
Establishing a reproducible, experimental human infection model of influenza virus transmission and evaluating interventions.
$3,479,305 / March 2023
University of Oxford
Evaluating treatments for severe and complicated influenza infections in hospitalized patients with RECOVERY FLU, a cost-efficient, adaptive platform clinical trial.
£11,416,263 / December 2022
University of Auckland
Leads a multidisciplinary and collaborative effort to observe and examine the reintroduction and transmission of influenza in New Zealand and identify novel immunological markers to inform influenza vaccine development.
11,340,572 NZD / December 2022, May 2021
Detect
Developing fast, accurate, and affordable molecular tests for routine use by everyone, including consumers in the home, employees in the workplace, and students at school.
Series C / November 2022, Series B / April 2021
Aarhus University Hospital
Leads INVITED, a multicenter, prospective randomized clinical trial among Type 1 diabetes patients to improve our understanding of the protective effect of influenza vaccination.
2,768,181 DKK / September 2024, October 2022
Protas
Reducing barriers to better treatments by designing and delivering high-quality, large-scale and global clinical trials at a fraction of current industry cost.
£5,000,000 / October 2022
NYC Virus Hunters
Creates an immersive approach to science education to unlock the potential of the next generation of influenza researchers in New York City.
$1,146,303 / July 2022, April 2020
Behavior Change for Good Initiative
Leverages the expertise of over 100 behavioral scientists to identify effective, scalable interventions for promoting immunizations.
$2,435,763 / March 2022, June 2021, October 2020
Virgina Tech
Leads the Multidisciplinary InvesTIGAtion of Transmission to Ease inFLUenza (MITIGATE FLU) study to transform our understanding of influenza virus transmission.
$8,792,291 / February 2022
Western Cooling Efficiency Center
Optimizing ventilation system operations to minimize airborne infectious disease transmission, pollutant exposure, and energy consumption.
$327,539 / November 2021
Center for Open Science
Leads multiple initiatives to promote open science and expand the publication of null and negative influenza research findings and replication studies.
$18,398,983 / August 2021, April 2020, August 2019
Sentinel Project
Develops ultra-sensitive genomic and CRISPR technologies to detect pathogens in multiple, connected settings to prevent pandemics before they start.
$5,000,000 / February 2021
Sentinel Project
Combines diagnostic technology and information-sharing platforms to connect early warning data to the public health community.
$11,250,000 / December 2020
Funding Opportunities
Flu Lab promotes innovation to speed the advancement of technologies and approaches for influenza, and we are open to receiving unsolicited pre-proposals at info@theflulab.org.